Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To determine the cost-effectiveness of second-line immune checkpoint inhibitors (ICIs) compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) using real-world patient-level treatment effectiveness, cost, and utility data.
Methods: Medical records of patients with NSCLC receiving second-line ICIs or chemotherapy at Siriraj Hospital, Bangkok, Thailand from January 2016 to May 2023 were reviewed to evaluate treatment effectiveness and direct medical costs. Patients receiving treatment from July 2023 to March 2024 were interviewed to determine utility and direct nonmedical costs. A semi-Markov model was used to analyze the lifetime costs and health outcomes from societal perspective. One-way and probabilistic sensitivity analyses and scenario analyses were performed.
Results: Data were collected from 209 patients (72 and 137 patients received second-line ICIs and chemotherapy, respectively). Second-line ICIs significantly improved overall survival (hazard ratio 0.64, 95% confidence interval 0.47-0.89, P = .008) and increased the quality-adjusted life-years (QALYs) from 0.54 to 1.11, resulting in QALY gain of 0.57; lifetime cost increased from 17 204 US dollar (USD) to 34 424 USD. Second-line ICI incremental cost-effectiveness ratio was 30 104 USD/QALY. Scenario analysis revealed that second-line ICIs were more cost-effective than chemotherapy for healthier patients (Eastern Cooperative Oncology Group 0-1) with incremental cost-effectiveness ratio of 9856 USD/QALY. Considering Thailand's willingness-to-pay threshold of 4444 USD/QALY, second-line ICIs could be cost-effective if the cost of atezolizumab was reduced by 86%.
Conclusion: Second-line ICIs significantly improved survival in advanced NSCLC but are not cost-effective in Thailand. Drug price negotiation and patient subgroup prioritization would help make second-line ICIs more accessible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vhri.2025.101172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in the immunological microenvironment and immunotherapy of bladder cancer.
Front Immunol
September 2025
Department of Urology, the First Affiliated Hospital of Harbin Medical University, HeiLongJiang Harbin, China.
Bladder cancer remains a significant global health challenge, particularly affecting male populations. While radical cystectomy and chemotherapy have been mainstays of treatment, their substantial morbidity and impact on quality of life have driven the development of bladder-preserving immunotherapeutic strategies. Clinical trial data support the use of ICIs as first-line therapy for cisplatin-ineligible patients, second-line treatment for platinum-refractory disease, and maintenance therapy.
View Article and Find Full Text PDFTreatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.
Melanoma Res
September 2025
Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Patients with mucosal melanoma have lower survival rates than those with cutaneous melanoma. Recent studies have reported lower mucosal melanoma survival rates with the use of immune checkpoint inhibitors (ICIs). This study analyzed ICI treatment outcomes in patients with mucosal melanoma in a real-world context.
View Article and Find Full Text PDFLenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights.
Cureus
July 2025
Pharmaceutical Chemistry, University of Lagos College of Medicine, Lagos, NGA.
Advanced endometrial cancer (aEC) presents a formidable therapeutic challenge, particularly in patients with recurrent or metastatic disease. Historically, platinum-based chemotherapy is the mainstay treatment for aEC. However, the treatment paradigm has shifted with the emergence of immune checkpoint inhibitors (ICIs) and targeted therapies.
View Article and Find Full Text PDFReal-World Effectiveness and Cost-Utility Analysis of Second-Line Immunotherapy for Non-Oncogene-Addicted Advanced Non-Small Cell Lung Cancer.
Value Health Reg Issues
August 2025
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address:
Objectives: To determine the cost-effectiveness of second-line immune checkpoint inhibitors (ICIs) compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) using real-world patient-level treatment effectiveness, cost, and utility data.
Methods: Medical records of patients with NSCLC receiving second-line ICIs or chemotherapy at Siriraj Hospital, Bangkok, Thailand from January 2016 to May 2023 were reviewed to evaluate treatment effectiveness and direct medical costs. Patients receiving treatment from July 2023 to March 2024 were interviewed to determine utility and direct nonmedical costs.
Baseline metabolic signatures predict clinical outcomes in immunotherapy-treated melanoma patients: a pilot study.
Front Immunol
August 2025
Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Background: Immune checkpoint inhibitors (ICIs) have improved the metastatic melanoma (MM) treatment. However, a significant proportion of patients show resistance to immunotherapy, and predictive biomarkers for non-responders or high-risk recurring patients are currently lacking. Recent studies have shown that tumor-related metabolic fingerprints can be useful in predicting prognosis and response to therapy in various cancer types.
View Article and Find Full Text PDF